Ionis Pharmaceuticals Inc (FRA:ISI)
€ 33.48 -0.13 (-0.39%) Market Cap: 5.40 Bil Enterprise Value: 4.42 Bil PE Ratio: 0 PB Ratio: 8.55 GF Score: 60/100

Ionis Pharmaceuticals Inc at Wells Fargo Healthcare Conference Transcript

Sep 05, 2019 / 01:45PM GMT
Release Date Price: €56 (-1.34%)
James William Birchenough
Wells Fargo Securities, LLC, Research Division - MD and Senior Biotechnology Analyst

We're going to get started with our next company, and it's my pleasure, on behalf of Wells Fargo Securities, to welcome the management from Ionis Pharmaceuticals. We have Beth Hougen, their Chief Financial Officer; and Wade Walke, their Head of Investor Relations.

Questions & Answers

James William Birchenough
Wells Fargo Securities, LLC, Research Division - MD and Senior Biotechnology Analyst

I can't think of a better company to do a fireside chat with than Ionis. I don't know that we're going to be able to fit it all in 30 minutes. But maybe just to set the table, Ionis is really the leader in the form of RNA therapeutics called antisense. They've got probably the broadest pipeline in biotech and several approved drugs, a really rapidly evolving business model. So maybe just to start off with Beth, if you could just speak to how you see Ionis today, how you think investors should think about Ionis from an investment perspective.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot